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We determined the genome-wide digital gene expression (DGE) proﬁles of primary acute lymphoblastic leukemia (ALL) cells
from 21 patients taking advantage of ‘second-generation’ sequencing technology. Patients included in this study represent four
cytogenetically distinct subtypes of B-cell precursor (BCP) ALL and T-cell lineage ALL (T-ALL). The robustness of DGE combined
with supervised classiﬁcation by nearest shrunken centroids (NSC) was validated experimentally and by comparison with
published expression data for large sets of ALL samples. Genes that were differentially expressed between BCP ALL subtypes
were enriched to distinct signaling pathways with dic(9;20) enriched to TP53 signaling, t(9;22) to interferon signaling, as well as
high hyperdiploidy and t(12;21) to apoptosis signaling. We also observed antisense tags expressed from the non-coding strand
of B50% of annotated genes, many of which were expressed in a subtype-speciﬁc pattern. Antisense tags from 17 gene
regions unambiguously discriminated between the BCP ALL and T-ALL subtypes, and antisense tags from 76 gene regions
discriminated between the 4 BCP subtypes. We observed a signiﬁcant overlap of gene regions with alternative polyadenylation
and antisense transcription (Po1 10
 15). Our study using DGE proﬁling provided new insights into the RNA expression
patterns in ALL cells.
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INTRODUCTION
Acute lymphoblastic leukemia (ALL) is a heterogeneous disease
that originates from lymphocyte progenitor cells of B- or T-cell
origin. ALL comprises multiple distinct subtypes that are
characterized by recurrent copy number alterations and structural
chromosomal rearrangements, which have important clinical
implications. Such cytogenetically distinct subtypes include
B-cell precursor (BCP) leukemias with the chromosomal transloca-
tions t(12;21)(p13;q22)[ETV6/RUNX1], t(9;22)(q11;q34)[BCR/ABL1],
dic(9;20)[p13;q11] and high hyperdiploidy (HeH) (450 chromo-
somes) karyotypes. It is well established that ALL subtypes differ
from a clinical perspective, but the underlying molecular
consequences of most of the recurrent chromosomal abnormal-
ities are poorly understood.
Expression microarrays have been applied for genome-wide
expression analysis for classiﬁcation of leukemia subtypes
1- -3 and
for identiﬁcation of differentially expressed genes associated with
drug resistance and treatment outcome in childhood ALL.
4
Although these studies provided new information regarding gene
expression patterns in ALL, genes and affected pathways may
have been missed because of technical limitations of hybridiza-
tion-based methods. Sequencing-based methods like serial
analysis of gene expression
5 generate absolute rather than
relative measurements of gene expression without the bias of
predesigned hybridization probes. Until recently, the cost and
throughput of capillary sequencing technology have hindered
their widespread use. The digital gene expression (DGE) proﬁling
method, based on similar principles as serial analysis of gene
expression, was made possible by the recent advances made in
‘second-generation’ DNA sequencing technologies.
6- -8 Today,
millions of expression tags can be measured simultaneously at a
fraction of the cost of capillary sequencing used in the original
serial analysis of gene expression method. A major advantage of
DGE, which overcomes the drawbacks of using predesigned
hybridization probes as in microarray-based methods, is that it
allows detection of expressed genes in a strand-speciﬁc manner.
9- -11
Thus, the DGE method provides information on the polarity of the
expressed transcripts, allowing detection of sense and antisense
transcripts from the same gene region.
Antisense transcripts are endogenous RNA molecules that are
transcribed from the noncoding DNA strand, on the opposite
strand of a gene. Like protein-coding transcripts, antisense RNAs
may contain a 50Cap and can be polyadenylated at the 30 end.
12,13
Sense--antisense transcripts arising from the same gene region
appear to be ubiquitously expressed in healthy and diseased
mammalian cells.
11,13,14 For example, systematic investigation of
antisense transcription by the FANTOM (Functional Annotation
of the Mammalian Genome) consortium revealed that up to 72%
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15,16
Sense--antisense transcript pairs have been observed in human
lymphocytes,
14 and using DGE of oligo-dT-captured RNA, the ratio
between sense--antisense transcripts has been found to differ
between cancer cells and normal matched tissues and between
cancer subtypes.
11 Focused studies on individual genes with
hematopoietic and pro-leukemic functions have uncovered
antisense RNAs that speciﬁcally modulate dosage of the sense
transcript.
17,18 Such antisense RNAs are likely to be involved in the
regulation of many protein-coding genes, which may be
important for leukemic progression. No genome-wide analysis of
antisense transcripts in primary ALL cells has so far been
conducted.
The presence of multiple DGE tags in a gene can be used to
identify transcripts with 30 untranslated regions (UTRs) of different
lengths. Widespread alternative polyadenylation (APA) in cancer
cells and the preferential use of shorter 30 UTRs in proliferating
cells have been observed.
19,20 Furthermore, antisense transcripts
and APA seem to be correlated.
21,22 The DGE method can detect
antisense transcripts and APA and could thus be an excellent tool
for investigation of these events in ALL cells. In this study, we
applied the DGE method for classiﬁcation analysis of ALL subtypes
and to detect subtype-speciﬁc antisense expression and APA in
ALL cells.
MATERIALS AND METHODS
Patient samples
Bone marrow or peripheral blood samples from 21 children with
ALL representing ﬁve cytogenetic subtypes of ALL were included
in this study (Table 1). Leukemic cells were isolated by 1.077g/ml
Ficoll-Isopaque (Pharmacia, Uppsala, Sweden) density-gradient
centrifugation. The proportion of lymphoblasts was X90% as
estimated by light microscopy of May-Gru ¨nwald-Giemsa-stained
cytocentrifugate preparations. RNA was extracted from frozen cell
pellets as described previously.
23 RNA samples had an average
RNA integrity number of 9.1 (minimum 7.8) according to
Bioanalyzer analysis (Agilent Technologies, Santa Clara, CA, USA).
The RNA was quantiﬁed by ultraviolet absorbance using a
ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington,
DE, USA). The regional ethics committee approved this study, and
patients and/or their guardians provided written informed
consent. This study was conducted in accordance with the
Helsinki Declaration.
Preparation of sequencing libraries
Sequencing libraries were prepared from 1mg of total RNA using
reagents from the NlaIII Digital Gene Expression Tag Proﬁling kit
(Illumina Inc., San Diego, CA, USA). mRNA was captured on
magnetic oligo(dT) beads and reverse transcribed into double-
stranded cDNA (SuperScript II, Invitrogen, Carlsbad, CA, USA). The
cDNA was cleaved using the restriction enzyme NlaIII. An adapter
sequence containing the recognition sequence for the restriction
enzyme MmeI was ligated to the NlaIII cleavage sites. The adapter-
ligated cDNA was digested with MmeI to release the cDNA from
the magnetic bead, while leaving 17bp of sequence in the
fragment. The fragments were dephosphorylated and puriﬁed by
phenol--chloroform. A second adapter was ligated at the MmeI
cleavage sites. Adapter-ligated cDNA fragments were ampliﬁed by
PCR, and PCR products were puriﬁed on a 6% polyacrylamide gel
(Invitrogen). The B96-bp PCR products were excised from the gel
and eluted overnight, followed by ethanol precipitation and
re-suspension (Illumina Inc.). Puriﬁed libraries were quality controlled
and quantiﬁed on a Bioanalyzer using DNA 1000 series or High-
Sensitivity chips (Agilent Technologies). DGE libraries were diluted
to a 10nM concentration and stored at  201C until sequencing.
Sequencing and data processing
Each DGE library was sequenced on an individual lane of a ﬂow
cell using an Illumina Genome Analyzer (GAII or GAIIx) for 18 cycles
using reagents from version 2 cluster generation kits and version 3
sequencing kits (Illumina Inc.). Image analysis and base calling
were performed using the Genome Analyzer pipeline v1.4. The
ﬁrst 17 bases of the tag sequences were extracted from the output
Table 1. Clinical characteristics of ALL patients
Sample ID Immunophenotype Genetic subtype
a Age at diagnosis (years) WBC
b Events
Patient 1 Pre-B dic(9;20) 1.7 93.7 CR1
Patient 2 Pre-B dic(9;20) 5.6 77.0 CR1
Patient 3 Pre-B dic(9;20) 6.3 NA CR1
Patient 4 Pre-B HeH 3.3 0.8 CR1
Patient 5 Pre-B HeH 8.9 95.0 CR1
Patient 6 Pre-B HeH 1.9 23.3 Relapse
Patient 7 Pre-B HeH 3.5 11.2 CR1
Patient 8 Pre-B HeH 14.1 5.0 Relapse
Patient 9 Pre-B HeH 3.1 3.0 CR1
Patient 10 Pre-B HeH 6 24.5 CR1
Patient 11 Pre-B HeH 3.8 39.6 Relapse
Patient 12 Pre-B t(12;21) 3.1 28.0 CR1
Patient 13 Pre-B t(12;21) 3.7 12.3 CR1
Patient 14 Pre-B t(12;21) 4.7 4.6 SMN
Patient 15 Pre-B t(9;22) 10.7 116.0 SMN
Patient 16 Pre-B t(9;22) 11.2 64.4 CR1
Patient 17 Pre-B t(9;22) 13.5 130.0 Relapse
Patient 18 T-ALL T-ALL 13.9 139.0 CR1
Patient 19 T-ALL T-ALL 13.4 66.5 Resistant disease
Patient 20 T-ALL T-ALL 10.8 234.0 DCR1
Patient 21 T-ALL T-ALL 17.2 126.0 CR1
Abbreviations: ALL, acute lymphoblastic leukemia; CR1, continuous ﬁrst remission; DCR1, dead in CR1; NA, not available; SMN, secondary malignant neoplasm;
T-ALL, T-cell lineage ALL; WBC, white blood cell.
aDic(9;20), dicentric chromosome (9;20)[p13;q11]; HeH, high hyperdiploidy; t(12;21), translocation between
chromosomes (12;21))(p13;q22)[ETV6/RUNX1]; t(9;22), translocation between chromosomes (9;22) (q11;q34)[BCR/ABL1]; T-ALL, T-cell ALL. ALL diagnosis was
established by analysis of morphology, immunophenotype and cytogenetics of leukemic cells. Fluorescence in situ hybridization and/or reverse-transcriptase
PCR were applied to identify t(12;21) and dic(9;20) rearrangements.
bWBC count at diagnosis (10
9 cells/l).
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score of 20, discarding tags if they had any base with a score
below 20. Unique tags were sorted and counted in each of the
DGE libraries using custom Perl scripts written for DGE analysis.
Annotation of sequenced tags
DGE tags were annotated to the human transcriptome (Ensembl
version 58) by mapping the reads to the sequence ﬂanking NlaIII
restriction sites on both coding and non-coding strands. Tags
matching more than one gene region were discarded. Tag counts
were normalized to tags per million (TPM) by dividing the raw tag
count by the total number of tags from each library and
multiplying by one million. The total expression proﬁle for each
gene was calculated by summing all tags mapped to the same
gene, including intronic tags (Supplementary Information). DGE
data are available online at the Gene Expression Omnibus under
accession number GSE26878. Previously reported sense/antisense
expressed sequence tags or mRNAs (n¼8652) were downloaded
from the Natural Antisense Transcripts Database (NATsDB, release
2006/2007).
24 A total of 8554 pairs remained after conversion
to Genome Reference Consortium human build 37 (GRCh37). All
uniquely annotated antisense tag sequences from DGE were
examined to assess whether they are located within a region
ﬂanked by previously observed pairs in NATsDB.
Identiﬁcation and analysis of APA
Genes with at least two uniquely annotated tags in the 30 UTR of the
last exon or within 1000bp downstream of the 30 gene boundary
were marked as potentially affected by APA. To compare the APA
detected by DGE with predicted polyA cleavage sites, we used the
Alternative Splicing and Transcript Diversity database (release 1.1
build 9), which contains 41024 APA sites.
25 A total of 41005 sites
remained after conversion to GRCh37. To investigate the presence
of micro-RNA (miRNA) target sites in the genes potentially affected
by APA, 54199 predicted seed regions were downloaded from the
TargetScan Human database (release 5.1),
26 52913 of which
remained after conversion to GRCh37.
Quantitative PCR
The expression levels of ﬁve genes determined by DGE were
validated by quantitative PCR with TaqMan gene expression
assays with FAM dye-labeled minor groove binding probes
(Applied Biosystems, Carlsbad, CA, USA). cDNA was synthesized
from 200ng of total RNA using the High-Capacity RNA-to-cDNA kit
(Applied Biosystems). Five ng of cDNA was used in each reaction
performed on a StepOnePlus Real-Time quantitative PCR system
(Applied Biosystems). Each cDNA was analyzed in triplicate and
the average Ct-value (DCt) was calculated per sample. Relative
expression levels were calculated with the 2
DDCt method.
27
YWHAH was used as an endogenous control, as it was the
housekeeping gene with the lowest s.d. in the DGE data.
Statistical analyses
Statistical analyses were performed in R using tools from
Bioconductor.
28 Hierarchical clustering was performed by conven-
tional agglomerative clustering (‘hclust’) with one minus the
correlation coefﬁcient as the distance measure for pairs of
individuals and average linkage as the measure of cluster
similarity. The gene lists were analyzed by ingenuity pathway
analysis (Ingenuity Systems, Redwood City, CA, USA). Ingenuity
pathway analysis P-values were calculated using Fisher’s exact test
by measuring the difference in proportion overlapping genes for
each function or pathway between the genes highlighted by a
particular analysis and the total number of genes measured by
DGE (17199 genes were pathway eligible). Pairwise comparisons
were performed with the software tool for empirical analysis of
DGE in R (edgeR).
29 Genes were called as differentially expressed
when their adjusted P-values were o0.05. P-values were adjusted
for multiple testing by the Benjamini and Hochberg approach. For
multivariate analysis of gene expression, the method of nearest
shrunken centroid (NSC) classiﬁers
30 as implemented in the
R package ‘pamr’ was used. P-values for the performance of the
classiﬁers were calculated by comparing the number of CV errors
in the real data with the number of CV errors in the shufﬂed data,
in which the subtype labels of the samples were randomly
permuted 1000 times.
31 The NSC scores reported here for each
subtype are also known as the shrunken differences,
30 which is a
standardized difference between the values of a given gene in the
global centroid and the shrunken (modiﬁed) centroid for each
subtype. For more details, see Supplementary Information.
RESULTS
Annotation of sequence tags
Taking advantage of the precise (digital) determination of gene
expression levels by ‘second-generation’ tag sequencing (DGE),
we generated expression proﬁles of cells taken at diagnosis from
17 patients with BCP ALL of four subtypes: high hyperdiploidy
(HeH) (n¼8), t(9;22) BCR-ABL1 (n¼3), t(12;21) ETV6-RUNX1 (n¼3),
dic(9;20) (n¼3) and four patients with T-cell lineage ALL (T-ALL)
(Table 1). We prepared DGE sequencing libraries using NlaIII as
the anchoring enzyme, and sequenced each of these libraries
using an Illumina Genome Analyzer, which yielded 4.9--23.7 million
quality-ﬁltered sequence reads (tags) per sample (Supplementary
Table S1). Omitting tags with abundance below 2 TPM, tags that
mapped to more than one gene and tags that had no match with
the reference transcripts in the Ensembl database, we obtained
20--46 thousand unique nucleotide sequence tags per library that
mapped to the transcriptome (Figure 1a, Supplementary Table S1).
In total, we observed a robust expression of 17313 genes with
tags X2 TPM in the 21 libraries from ALL cells. The dynamic
range for the gene expression measured by DGE was broad,
ranging from 2--7.3 10
4 TPM (Figure 1b), which corresponds
to 0.7--2.2 10
4 transcripts per cell, assuming that one transcript
per cell is roughly equal to one transcript in 3 10
5.
32 Replicate
assays from different stages of the DGE procedure conﬁrmed
the reproducibility of the expression measurements using DGE
(Supplementary Figure S1).
To benchmark DGE against the most commonly used method
for gene expression analysis, we compared the DGE levels of 12
RNA samples with expression levels from Affymetrix GeneChips
(Affymetrix, Santa Clara, CA, USA). Correlation between the gene
expression levels measured by the two platforms was r¼0.61,
indicating that DGE proﬁles are comparable to those from the
Affymetrix GeneChips. DGE detected 22% more genes (n¼3251)
with low average expression levels of B10.7 TPM and had a
15-fold wider dynamic range than hybridization on GeneChips
(Supplementary Information and Supplementary Figure S2).
Utility of DGE and NSC to classify ALL subtypes
We applied supervised classiﬁcation by NSC
30 to obtain DGE
signatures that are characteristic of ALL subtypes. NSC classiﬁca-
tion selected a set of 20 genes to distinguish between the BCP and
T-ALL samples (Supplementary Table S2) and a set of 34 genes to
distinguish between the BCP subtypes HeH, t(9;22), t(12;21) and
dic(9;20) (Supplementary Table S3). Applying NSC for comparing
BCP ALL cells against T-ALL cells resulted in an average of 1/21
cross-validation errors (Po0.001), and the multivariate analysis of
BCP ALL subtypes resulted in an average of 2.6/17 cross-validation
errors (Po0.001), indicating that the classiﬁer did not classify the
samples by chance. Evidence for the robustness of DGE was
provided by perfect separation between the ALL subtypes by
hierarchical clustering of samples according to gene sets
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by NSC were validated by quantitative PCR. For each gene and
subtype, the relative expression levels determined by quantitative
PCR and expressed tag count determined by DGE were consistent
(Figure 3).
We used the Oncomine tool
33 to mine published gene
expression data sets for differentially expressed genes detected
here by NSC of the DGE data. In addition to the Oncomine data
sets, we included two additional expression data sets. Taken
together, expression data from 41600 ALL patients validated the
differential expression of 17 of the 20 genes between the BCP ALL
and T-ALL subtypes (Supplementary Table S4). In all, 18 of 34 BCP
ALL subtype-speciﬁc genes were validated in B750 ALL samples
(Supplementary Table S5). The overlap of differentially expressed
genes between our relatively small number of samples and genes
reported by multiple studies of large ALL sample sets and provides
evidence for the robustness and biological relevance of the genes
identiﬁed here by DGE in combination with NSC.
The 54 genes selected by the 2 classiﬁers are enriched for
higher-order molecular and cellular functions such as cell
signaling (n¼7, Po0.001), cellular assembly and organization
(n¼7, Po0.05), as well as cell death (n¼14, Po0.0026), which are
relevant for the ALL phenotype. Four of the genes (namely ASS1,
GAB1, SOX11 and THBS1) are known as diagnostic or prognostic
markers for other hematological malignancies,
34- -37 but have not
previously been studied as markers for ALL. Pairwise analyses of
the DGE data from the four subtypes of BCP ALL distinguished
differentially expressed genes, which point at distinct pathways in
HeH, t(9;22), t(12;21) and dic(9;20) ALL (Supplementary Table S6).
The p53 signaling pathway was highlighted in cells of the dic(9;20)
subtype, genes from the interferon signaling and innate immunity
systems were highlighted in t(9;22) cells, differential regulation of
anti-apoptosis genes was highlighted in t(12;21) cells and
apoptosis signaling in HeH cells (Table 2).
Quantiﬁcation of antisense transcripts in ALL cells
We took advantage of the strand speciﬁcity of DGE to measure
antisense expression in ALL cells. We detected a total of 30150
antisense tags at a level X2 TPM, which corresponds to antisense
transcription of 48.6% of the expressed gene regions (Figure 1a).
The correlation between the antisense expression levels measured
across all gene regions in replicate libraries from the same RNA
sample was high (r¼0.70, Figure 4a). More than 30% of the
antisense tags observed in ALL cells were located within the
borders of a previously described sense/antisense transcript pair
in the Natural Antisense Transcript database.
24 The antisense
transcripts were expressed at substantial levels (2--1.7 10
3 TPM),
but in most cases, they were less abundant than sense transcripts
(Figure 1b). However, we observed higher antisense expression
levels for 6.5% (549/8405) of the sense/antisense gene pairs. The
correlation between expression levels of sense and antisense tags
originating from the same gene region varied over a broad range,
from perfectly correlated (r¼1.0) to strongly anti-correlated
(r¼ 0.7) pairs (Figure 4b). The absence of a systematic
correlation between reciprocal sense--antisense pairs indicates
that transcription from the antisense strand is either concordant
with transcription in the sense orientation or discordant. This is
consistent with observations in other studies of different
tissues.
38,39 In addition, 173 genes were detected only by
antisense tags.
Classiﬁcation of ALL subtypes by antisense transcripts
We performed supervised classiﬁcation with NSC to identify gene
regions with subtype-speciﬁc antisense transcripts. NSC deﬁned
19 antisense tags expressed in 15 gene regions that distinguished
the T-ALL and BCP ALL subtypes (Po0.001) (Supplementary Table
S7) and 83 antisense tags expressed in the antisense orientation of
76 gene regions (Po0.001) that distinguished the 4 BCP ALL
subtypes (Supplementary Table S8). Analogously to genes
expressed in the sense direction (Figures 2a and b), hierarchical
clustering of samples by antisense tags selected by the classiﬁer
resulted in perfect separation of the samples according to their
respective subtypes (Figures 2c and d). The majority of gene
regions highlighted by NSC classiﬁcation of antisense tags were
different from those highlighted by expression in the sense
direction. An exception is the SOX11 gene that was identiﬁed as
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Figure 1. Distribution between gene locations and abundance of
annotated tags. To annotate the sequenced tags, we created a
database of all possible 17-bp tag sequences next to an NlaIII site
from the Ensembl transcriptome database. (a) The bars show the
proportion of the total number of tags by location in gene regions.
The canonical location refers to the tag originating from the most 30
NlaIII site in a gene, to which 41% mapped. Overall, 22% of the tags
were mapped to exons, which may represent transcript isoforms
that are not listed in Ensembl. In all, 3.4% of the tags, which
presumably originate from unprocessed pre-mRNA transcripts,
mis-spliced transcripts, or unannotated exons, were annotated to
intronic gene sequences. Overall, 3.6% of the sequenced tags
mapped in an antisense orientation to gene regions in the Ensembl
database. The remaining tags had multiple annotations (23%) or
were not found in our database of possible tag sequences (7%). No
signiﬁcant difference in the distribution between gene locations was
observed for the annotated tags between the ALL subtypes (data
not shown). (b) The bars show the proportion of annotated tags at
different bins of expression levels. The expression levels are in tags
per million (TPM) on a log2- transformed scale on the horizontal
axis. Black bars indicate tags annotated to genes in the sense
direction and light gray bars indicate tags annotated to genes in the
antisense direction.
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Figure 2. Hierarchical clustering of ALL samples according to gene regions deﬁned by nearest shrunken centroid (NSC) classiﬁcation based
on DGE data from sense and antisense transcripts. (a) Heatmap of the expression levels of the 20 genes deﬁned by the NSC classiﬁer for
discriminating between the samples of BCP and T-ALL subtypes. These genes are listed in Supplementary Table S2. (b) Heatmap of the
expression levels of 34 genes deﬁned by the NSC classiﬁer for discriminating between the 4 BCP subtypes. The 34 genes are listed in
Supplementary Table S3. (c) Heatmap of the expression levels of 19 antisense expressed tags deﬁned by the NSC classiﬁer for discriminating
the samples with BCP and T-ALL subtypes. The tags and corresponding gene regions are listed in Supplementary Table S7. (d) Heatmap of
the expression levels of 83 antisense expressed tags deﬁned by the NSC classiﬁer for discriminating the BCP subtypes, the tags and
corresponding gene regions are listed in Supplementary Table S8. ALL samples are shown in horizontal rows, and genes are shown in vertical
columns. The color code for the BCP vs T-ALL comparisons (panels a and c) is shown in the upper right corner of panel a. BCP samples are
indicated in light gray and T-ALL samples are indicated in dark gray. The color code for the BCP subtypes comparisons (panels b and c)
is shown in the upper right corner of panel b as follows: t(9;22) samples (n¼3) are indicated in light pink, HeH samples (n¼8) are indicated
in light blue, t(12;21) samples (n¼3) are indicated in dark yellow and dic(9;20) samples (n¼3) are indicated in dark blue. The color code for
the gene expression levels as number of transcripts per million (TPM) is shown on the right-hand side of each Heatmap.
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sense and antisense orientations. SOX11, a non-B-cell lineage
transcription factor encoded by an intron-less gene (Figure 5), is
involved in the regulation during embryonic development and in
the central nervous system. The SOX11 protein is expressed in a
subset of mantel cell lymphoma patients, in whom elevated
expression marks better overall survival.
35,40,41 Genes highlighted
by antisense tags and subtype-speciﬁc sense genes belong to
similar functional categories, like hematological system develop-
ment (n¼20, Po0.049) and cell death (n¼18, Po0.037). Notably,
antisense transcription of the important hematological regulators
NOTCH3 and PAX5 was observed in T-ALL cells and BCP ALL cells,
respectively. Sense and antisense transcription from the SOX11
and PAX5 gene regions were subsequently validated by strand-
speciﬁc reverse transcription and PCR (Supplementary Figure S3,
Supplementary Table S9, Supplementary Materials and methods).
The result for antisense transcription at the NOTCH3 locus was
inconclusive.
In light of recent ﬁndings of sense/antisense ratios that differ
between normal and malignant tissues,
11,42 we investigated
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Figure 3. Validation of digital gene expression (DGE) levels by quantitative PCR (qPCR). The RNA expression levels of ﬁve genes (a) KIR3DX1,
(b) DDIT4L,( c) NRTN,( d) THBS1 and (e) LRP12 highlighted in the NSC classiﬁcation analysis were determined by qPCR. Three dic(9;20),
t(9;22), HeH and T-ALL and two t(12;21) samples were analyzed by qPCR (see Table 1 for patients). The relative amounts of qPCR products
are plotted in each panel to the right and the DGE measurements in transcripts per million (TPM) are plotted to the left. For each qPCR,
one of the samples from the relevant subtype was selected as the reference for normalization. The relative expression levels measured by
qPCR for the remaining samples were calculated in relation to this sample. The error bars show the maximum and minimum relative
expression levels observed for each subtype. The DGE value in transcripts per million (TPM) for each gene in each sample is plotted by
subtype on the left side of each panel. The error bars show s.d. for the TPM values. (f) Correlation between the expression levels measured
for each of the ﬁve genes in each RNA sample using DGE and qPCR. The DCt values (quantity of target gene/quantity of endogenous control)
from qPCR are plotted on the vertical axis against the DGE levels in TPM on the horizontal axis. A strong inverse correlation (r¼ 0.68)
between DCt value and DGE expression is observed.
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or between all the BCP ALL cells as one group and T-ALL cells.
Although we observed a subset of 272 genes with differences in
the sense/antisense ratios between subtypes, this result did not
reach statistical signiﬁcance (Po0.05) after multiple testing
correction (data not shown).
Use of APA in ALL cells
Alternative polyadenylation (APA) changes the length of the 30
UTR of genes, which leads to the expression of mRNA isoforms of
different lengths. If the isoform length differs by at least one NlaIII
site, these different transcripts are detectable in the DGE data as
multiple expressed 30 tags in a gene region. We detected signs
of APA in 38.2% (6619) of the expressed genes. Of the pairs
of consecutive expressed tags in the 30 UTR of the last exon or
ﬂanking region, 17% were supported by the presence of a
predicted polyA cleavage site between the tags.
25 One of the
functional consequences of shorter 30 UTRs is increased stability of
a transcript as a result of the loss of miRNA-binding sites.
20 Using
available data on predicted miRNA target sites,
26 we found that
genes with APA contained signiﬁcantly more miRNA target sites
than did genes without evidence of APA (Po1 10
 15), suggest-
ing that APA in ALL cells may have a major effect on miRNA-
mediated regulation of gene expression. Interestingly, we
observed that genes with APA are also more likely to have
antisense tags in the same gene region (Po1 10
 15). These
ﬁndings suggest that APA, the presence of miRNA-binding sites
and antisense transcripts may be spatially or functionally
connected and important for gene regulation in ALL cells.
We did not observe subtype-speciﬁc patterns for genes with
APA. Instead, when analyzing the 1687 genes with exactly two
tags in the 30 UTR or ﬂanking region, we found 148 genes with
preferred short 30 UTRs and 679 genes with preferred longer 30
UTRs. The genes with preferred shorter 30 UTRs compared with the
genes with preferentially longer 30 UTRs are enriched for functions
in cell-cycle control, cellular assembly and organization, DNA
replication, recombination and repair (Po0.05). For a gene list and
functional annotation of the genes with shorter 30 UTRs, see
Supplementary Table S10.
DISCUSSION
In this study, we determined the genome-wide gene expression
proﬁles of 21 primary ALL cell samples by ‘second-generation’
sequencing of short cDNA tags. We demonstrate that
this unbiased, sequencing-based approach not only allows
precise genome-wide expression proﬁling but also provides
novel information on gene expression in ALL cells by detecting
antisense transcripts and APA.
The pathway-enrichment results from the dic(9;20) subtype are
particularly interesting. Although dic(9;20) is an established
recurrent chromosomal aberration with an estimated prevalence
of B5% of ALL cases in the Nordic countries,
43 no genome-wide
expression studies have been performed on this subtype. No fusion
Table 2. Pathway enrichment of genes with differential expression between BCP ALL subtypes
Subtype IPA
a P-value
b Pathway-associated genes
c (upregulated/downregulated)
dic(9;20) TP53 signaling 0.032 CDKN2A(  ), CSNK1D(+), CTNNB1(+), LRDD(+),
TP73(+++), JUND(+), JUNB(+)
t(9;22) Interferon signaling 0.000089 IFIT1(++), IFIT3(+), IRF9(+), OAS1(+), STAT1(+), STAT2(+)
Activation of IRF by cytosolic pattern
recognition receptors
0.00034 DHX58(+), IFIT2(+), IRF9(+), NFKB2(+), NFKBE(+), STAT1(+), STAT2(+)
Role of RIG1-like receptors in antiviral
innate immunity
0.002 CASP8(+), CASP10(+), DHX58(+), NFKB2(+), NFKBE(+)
t(12;21) Anti-apoptosis 0.0026 BAG3(+), BCL2L1(+), BIRC7(++),CD27(+)
VDR/RXR activation 0.014 KLF4(+), NCOR2(+), PDGFA( ), PRKCQ(+)
HeH Apoptosis signaling 0.00081 BCL2L1( ), CAPN2(+), CAPN3( ), CASP8( ), CASP10( ),
NFKB2( ), NFKBIB( ), NFKBIE( ), PRKCQ( )
OX40 signaling 0.004 BCL2L1( ), HLA-DOB(  ), NFKB2( ), NFKBIB( ), NFKBIE( ), TNFSF4( )
Abbreviations: ALL, acute lymphoblastic leukemia; IPA, ingenuity pathway analysis; IRF, interferon-regulatory factor; RIG1, retinoic acid inducible gene-I;
VDR/RXR, vitamin D3 receptor/retinoid X receptor.
aIPA canonical pathways or IPA tox lists.
bFisher’s exact test P-value.
cGene symbol according to
HUGO Gene Nomenclature Committee (http://www.genenames.org/). (+) Indicates signiﬁcant upregulation. An increasing number of (+) signs indicates
stronger upregulation. ( ) Indicates signiﬁcant downregulation. An increase in the number of ( ) signs indicates stronger downregulation.
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Figure 4. Detection of antisense transcription by digital gene
expression (DGE). (a) Positive correlation between expression
levels of antisense tags in DGE replication experiments from the
same ALL patient RNA sample (Pearson’s correlation coefﬁcient
r¼0.70). (b) Lack of systematic correlation between sense and
antisense expression from the same gene loci. Each dot represents
one gene. Pearson’s correlation coefﬁcients for each gene with
sense and antisense transcription are plotted on the y axis.
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aberration are heterogeneous, suggesting that the resulting loss
of DNA at the 9p or 20q regions may have a functional role.
44,45
The differentially regulated genes that we identiﬁed in dic(9;20)
cells were enriched to the TP53 signaling pathway. In each of the
three samples of the dic(9;20) subtype, we observed speciﬁc
downregulation of CDKN2A on chr 9p21. CDKN2A encodes two
tumor-suppressor proteins, namely p16
INK4a and p14
ARF, and is
frequently deleted in BCP ALL.
46- -48 SMAD1, which also belongs to
the TP53 pathway, was downregulated in parallel with CDKN2AA; a
similar correlation has been reported in ALL samples with 9p
deletions,
49 but not speciﬁcally in samples with dic(9;20). JUNB,
JUND and TP73, which inhibit TP53
50 were also overexpressed. In
the dic(9;20) subtype, the antisense transcripts at the LIN9 and
JUND gene regions were upregulated and downregulated at the
PSMD10 region. The proteins encoded by LIN9 and JUND interact
with genes in the TP53 signaling pathway, and PSMD10 is
speciﬁcally involved in TP53 degradation,
51 further pointing at the
importance of this signaling pathway in ALL patients with the
dic(9;20) subtype.
Different anti-apoptotic mechanisms in the HeH and t(12;21)
subtypes were suggested by the genes highlighted in the pairwise
analyses. The HeH subtype is characterized by 450 chromosomes
in leukemic cells, but whether the aneuploidy is a cause or a
consequence of the leukemic transformation is unclear.
52 In our
HeH samples, seven genes involved in signaling pathways that
regulate apoptosis were differentially expressed. Six genes were
downregulated in HeH cells, including BCL2L1 and PRKCQ that
arrest cell-cycle progression.
53,54 As aneuploidy arises from
aberrant control of mitotic checkpoints, we speculate that the
lower expression of such genes may contribute to the HeH
phenotype. In t(12;21) cells, DGE identiﬁed four upregulated genes
in anti-apoptosis signaling, including BCL2L1, BAG3, CD27 and
BIRC7. Genes in the BCL2 family can act as anti- or pro-apoptotic
regulators, and the longer isoform of BCL2L1 acts as an apoptosis
inhibitor, whereas the shorter isoform acts as an apoptotic
activator.
55 We could not distinguish between the isoforms
because they share the same 30 UTR sequence; however, we
observed the highest expression coming from the most 30 tag in
the gene for the t(12;21) samples (average 51.1 TPM), indicating
that the transcript with the longer 30 UTR is predominantly
transcribed. The genes in the pathways highlighted in t(9;22) cells
include STAT1, STAT2, IRF9, NFKBE and NFKB2, all of which are
upregulated and belong to the JAK/STAT signaling cascade
(Table 2).
The results from our study provide a basis for further functional
studies of regulatory RNA molecules that may affect the malignant
transformation of precursor B cells into ALL cells. Antisense
transcripts are remarkably abundant in primary ALL cells, with
antisense transcription of B49% of the expressed genes. More
than 30% of the antisense transcripts identiﬁed here have been
observed previously, indicating that the antisense transcriptome
in ALL overlaps with that in other cell types. Many of the antisense
loci identiﬁed here are reported for the ﬁrst time, presumably
because antisense transcription has not been previously investi-
gated on a genome-wide scale in primary ALL cells. As we used
oligo-dT capturing and many RNAs lack polyA tails, we most likely
underestimate the actual contribution of antisense transcripts in
ALL cells. Aberrantly expressed antisense transcripts may con-
tribute to disease by inducing chromosomal changes,
56 through
DNA--RNA interactions, or through transcription interference.
57
For example, the tumor-suppressor gene P15 has an antisense
RNA that silences the P15 gene through epigenetic alteration of
heterochromatin in leukemia cell lines.
18 We observed antisense
expression from genes known to have critical roles in cell death
and regulation of gene expression in leukemia, such as the PAX5
and NOTCH3 genes. PAX5 is a target of somatic mutations in BCP
ALL,
58 and the Notch pathway is frequently activated in T-ALL.
59
Both these genes are lineage-speciﬁc regulators at early stages of
B/T-cell development. In addition, SOX11 has been implicated as
an important growth regulator in hematological malignancies.
41
In our study, we also observed extensive APA and a strong
association between genes with APA and antisense expression in
the same gene region (Po1 10
 15). The extent and regulatory
function of antisense transcription and APA in ALL may be clariﬁed
in greater detail by strand-speciﬁc transcriptome sequencing,
which has become feasible only recently.
Complete transcriptome sequencing will be highly informative
in future studies of ALL and other malignancies because it
provides information on transcript sizes, isoforms and expression
of fusion genes, but DGE has some important practical advantages
over transcriptome sequencing. First, DGE requires less RNA than
most other transcriptome sequencing methods, and second, the
computational analysis of DGE data is less challenging. Taking
advantage of the increasing capacity of ‘second-generation’
sequencing technologies, DGE could easily be scaled up using
indexing to allow inexpensive and rapid digital expression
proﬁling in large sample collections.
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